

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited

新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 6108)

2024 ANNUAL REPORT – SUPPLEMENTAL INFORMATION

Reference is made to the annual report of New Ray Medicine International Holding Limited (“**Company**”, together with its subsidiaries, the “**Group**”) for the year ended 31 December 2024 (“**2024 AR**”). Capitalised terms used in this announcement shall have the same meanings as those defined in the 2024 AR.

It is disclosed in the 2024 AR that the Group’s financial assets at FVTPL include its investment in Shengzhou Xin Rui Wan Ma, the fair value of which accounted for approximately 5.9% of the Group’s audited total assets as at 31 December 2024. The Company wishes to supplement that such investment is held through the Group’s holding of 39 ordinary shares of, representing 39% of, the paid up capital of New Ray Wanma International Holding Company Limited (“**New Ray Wanma**”). New Ray Wanma is the ultimate holding company holding the entire paid up capital of Shengzhou Xin Rui Wan Ma.

For the history, cost of investment and fair value as at year end date the above investment and its performance during the Year, the principal businesses of the underlying company and the Company’s investment strategy for such investment, please refer to the relevant disclosures in the paragraph headed “MANAGEMENT DISCUSSION AND ANALYSIS – Financial Review – Financial Asset At FVTPL” and Note 18(iv) to the notes to the consolidated financial statements for the year ended 31 December 2024 the 2024 AR.

On behalf of the Board
New Ray Medicine International Holding Limited
Wang Qiuqin
Chairman & Executive Director

Hong Kong, 16 October 2025

As at the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Chu Xueping and Ms. Zhou Wan; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.